Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs are engineered...

Full description

Bibliographic Details
Main Authors: Astero Klampatsa, Andrew R. Haas, Edmund K. Moon, Steven M. Albelda
Format: Article
Language:English
Published: MDPI AG 2017-09-01
Series:Cancers
Subjects:
immunotherapy
chimeric antigen receptor T cells
mesothelioma
adoptive cell transfer
Online Access:https://www.mdpi.com/2072-6694/9/9/115

Similar Items

Similar Items